Nucana Plc Net Income per Employee (NCNA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Nucana Plc  (NASDAQ: NCNA)
 

Nucana Plc Net Income per Employee

NCNA's Quarterly Results, Trends, Rankings, Statistics
Nucana Plc recorded a cumulative net loss of $-71 million during 12 month ending in the fourth quarter 2025.
The Healthcare sector has seen employees of 421 other companies achieving higher income per employee. While Nucana Plc's total ranking has deteriorated compared to the previous quarter from 0 to 4610.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NCNA Net Income per Employee (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -5,910,134 -4,706,688 -4,706,688 -2,758,938 -2,758,938
NCNA's Total Ranking # 4610 # 0 # # #
Seq. Net Income Change - - - - -

NCNA Company Profile >> Back to NCNA Efficiency Comparisons >> Compare NCNA Net Income per Employee to its Competitors

NCNA Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 422
Healthcare Sector # 909
Overall Market # 4610

Net Income per Employee Statistics
High Average Low
$ -1,153,333 $ -2,132,117 $ -3,377,750
(Dec 31 2018)   (Dec 31 2021)




  News about Nucana Plc Income per employee

Evaluating NUC-7738s Potential Against Competitors Amidst Revenue Declines Insights from ESMO Congress 2025

: This article aims to present an analysis of the latest findings regarding NUC-7738, a promising therapeutic modality developed by Nucana Plc, as showcased at the ESMO Congress 2025. The article will shed light on the encouraging data related to the drug s efficacy in combination with PD-1 inhibitors, juxtaposed with the company’s recent financial performance compared to its competitors. Nucana Plc, a biotechnology company engaged in developing innovative cancer therapies, recently presented data at the ESMO Congress 2025 concerning its investigational drug, NUC-7738. This drug is being explored for its synergistic effect when combined with PD-1 inhibitors and its potential role in enhancing the efficacy of cancer treatments. However, despite promising clinical trial results, Nucana has faced significant challenges, as evidenced by a reported revenue decline.




Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2025Number of Employees Dec 31 2025


Date modified: 2026-09-09T12:37:50+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.